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As a common deposit for tumor cells, the liver is second only 
to the lymph nodes as a site of metastatic disease. The liver 
is also the most common site of metastatic disease in cancers 
of the large intestine because it is the first major organ 
reached by venous blood draining from the intestinal tract.  
Unfortunately, by the time some patients present with liver 
metastases there is usually evidence of the extensive 
systemic spread of the disease, and patients can no longer be 
considered as candidates for surgery or other local ablative 
treatments. However, there is a subset of patients with a few 
metastases (oligometastases) in which the role of a radical 
local treatment such as stereotactic body radiation therapy 
(SBRT) could change disease progression (1).   
Most patients with liver metastases have a well-preserved 
liver function with absence of underlying diseases. Prediction 
of hepatic toxicity after SBRT in these patients have been 
primarily based on the assumption of a parallel architecture 
where subvolumes of the organ function relatively 
independently and a fraction of the organ can be damaged 
without clinical effect. A complication is only observed if 
more than a critical volume is damaged (2). A critical volume 
of 700 ml of healthy liver (liver-GTV) receiving a total dose of 
less than 15Gy in 3 fractions has been broadly adopted to 
avoid hepatic toxicity (3). 
An accurate correlation between imaging and pathology is 
essential for target definition in SBRT. A good agreement 
between macroscopic pathology and MR imaging has been 
found for a group of colorectal liver metastases, suggesting 
that MR can be used for accurate tumor delineation (4). Pilot 
studies have reported positive integration of 4D PET-CT in 
the target delineation of liver metastases. 
The liver moves with respiration, and can change position 
depending of filling in adjacent anatomical structures. 
Assessment of motion of tumor or tumor surrogates (fiducial 
markers) is mandatory for liver SBRT (5). Management of 
breathing motion during planning and/or treatment 
(abdominal compression, active breathing control, gating, 
tumor tracking) and image guided techniques for daily 
repositioning are required to increase treatment accuracy, 
and make possible to deliver very high doses to the tumor 
while protecting the surrounding organs at risk. 
High local control rates after SBRT for liver metastases have 
been reported in several phase I-II and retrospective trials 
showing a local control between 80% and 100% at 2 years (6-
8).  
The American Association for Physics in Medicine has 
organized an SBRT working group (WGSBRT) to assess tumor 
control probability (TCP) and normal tissue control 
probability (NTCP) values for SBRT applied to different 
organs. In the case of liver metastases, the working liver TCP 
group investigated if outcomes were affected by the dose 
regimen. Local control outcomes were significantly better at 
3 years for BED >100Gy10. 
Toxicity reported after SBRT for liver metastases is in general 
limited. Quality of life has been assessed after liver SBRT 
showing no significant change between baseline and 1, 3, and 
6 months after treatment (9). 
Conclusion: High precision SBRT is an effective technique for 
treatment of liver oligometastases. Using the right dose, 
excellent local control rates can be achieved with limited 
toxicity and without impairment of quality of life.  
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The treatment strategies for many metastatic cancers are 
undergoing a dramatic paradigm shift.  Systemic therapies 
are increasingly tailored to unique characteristics of 
individual tumors.  Routine testing for genetic mutations and 
rearrangements are identifying patients who can benefit from 
“targeted” therapies.  Histology driven chemotherapy is 
commonly being used.  The advent of highly active immune 
modulating therapies have altered treatment strategies for 
many diseases that once had few good systemic options.   
Simultaneously, there is a growing belief that the number 
and location of metastases should also be considered in 
addition to molecular, histology, or immune related factors.  
Patients with metastases limited in number and destination 
organ, oligometastases, are often considered for surgery 
and/or radiation due to reports of long disease free intervals 
following treatment of all known metastases.  Across many 
diseases, it is common to see 20-25% of patients treated for 
limited metastatic disease alive and disease free years later. 
Systemic therapies are often reserved for patients with more 
widespread or “polymetastases”. 
Breast cancer patients often present with limited 
metastases.  Approximately 50% of patients treated on 
clinical trials had 2-4 sites of disease at enrollment.  
Additionally, breast cancer patients with limited metastases 
have improved survival compared to those with more 
extensive metastases.  Following treatment of all known 
metastases median survivals are numerically higher than 
historic populations.  Therefore, NRG BR002 is randomizing 
patients with 1-2 breast cancer metastases to ablative 
therapy (surgery or radiation) plus standard of care therapy 
vs standard of care therapy alone.   
Oligometastases are also common in NSCLC.  A prospective 
phase II study demonstrated long term survivors in patients 
treated with radiotherapy or surgery for oligometaststic 
disease.  Multiple randomized studies have been attempted 
in this population to test consolidation with radiation 
following systemic therapy as well as radiation integrated 
into a systemic therapy treatment platform, however both 
have failed to accrue.  An increasingly useful strategy in 
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NSCLC patients with known targetable molecular mutations is 
treatment of limited metastatic progression or 
oligoprogression.  This is due to the fact that most patients 
with treatable mutations in NSCLC progress in a limited 
number of metastases.  Ablation of these metastases has 
been shown to allow patients to remain on therapy longer 
thereby extending the time to the next line of therapy.  
Melanoma and Renal Cell Carcinoma, classically described 
“radioresistant” histologies, respond well to ablative 
radiation.  Ablation of all known metastases has resulted in 
high (80-90%) rates of treated tumor control.  Comparative 
analyses of metastastic melanoma patients treated with 
metastasectomy versus standard of care demonstrated 
improved survival for those treated with removal of 
metastases.  However this was prior to the advent of 
improved immunomodulatory and targeted agents for 
metastatic melanoma.  Furthermore, treatment of 
oligometastases with radiation has the potential to act as an 
immunosensitizer, stimulating the immune system and 
enhancing the response to immunomodulatory agents, 
perhaps inducing an abscopal effect.  
Evidence also shows that oligometastases are common in 
prostate cancer.  Ongoing studies are determining if ablative 
therapy to all known prostate oligometastases can delay the 
onset of androgen deprivation therapy, limiting the time, 
side effects and cost associated with treatment. 
 There are other roles for treatment of oligometastases 
beyond improvements in survival vs standard therapies.  Many 
patients are not candidates for standard therapies due to 
medical comorbidity.  Other patients, intolerant of the side 
effects of “targeted therapies”, are left with few treatment 
options.  Ablation of all metastases through surgery if 
feasible and possible or radiation can serve as another line of 
therapy to prolong disease free intervals.   
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Although the term 'oligometastasis' was coined in the 1990's, 
the first reports of treating limited metastatic disease with 
surgical resection originated six decades earlier. Several 
modalities are available to treat metastatic lesions, including 
surgical resection, stereotactic radiotherapy, conventional 
radiotherapy, and radiofrequency ablation. 
Numerous studies have reported 'better than expected' 
survival outcomes after ablation of limited metastatic 
disease, encompassing patients with varied histologic 
subtypes and metastatic locations. However, significant 
controversies remain, as it is unclear as to the extent of 
which the 'better than expected' survival is due to the 
treatments themselves, or merely due to selection of very fit 
patients with indolent-behaving tumors. The goal of this 
presentation is to review the uncertainties associated with 
the oligometastatic state, the natural history of untreated 
oligometastatic disease, current and past clinical trials, and 
future areas of research.  
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It is thought that ablative radiotherapy (RT), used for rapid 
control tumor growth, induces genotoxic stress and mitosis 
crisis leading to prolonged dormancy of irradiated tumor at 
local and distal site in most patients. We have unexpectedly 
observed that initial reduction of tumor burden following 
ablative RT also depends largely on type I IFN for CTL.  
Targeting tumor with IFN can control tumor growth through 
initiating a coordinated innate and adaptive immune attack 
against tumor cells.  However, the mechanism for radiation-
mediated type I IFN induction remains unclear. Here, we 
demonstrated that STING, but not MYD88, was required for 
type I IFN-dependent antitumor effects of radiation. STING in 
dendritic cells (DCs) controlled radiation-mediated IFN-β 
induction and was activated by irradiated-tumor cells. The 
cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) 
mediated DCs sensing of irradiated-tumor cells. Moreover, 
STING was essential for radiation-induced adaptive immune 
responses, which relied on type I IFN signaling on DCs. 
Exogenous IFN-β treatment rescued cGAS/STING-deficient 
immune responses. Accordingly, enhancing STING signaling by 
cGAMP administration promoted antitumor efficacy of 
radiation. Our results reveal that the molecular mechanism 
of radiation-mediated antitumor immunity depends on a 
proper cytosolic DNA-sensing pathway, pointing towards a 
new understanding of radiation and host interactions. 
Furthermore, we uncover a new strategy to improve 
radiotherapy by cGAMP treatment.  RT induced IFN can also 
upregulate PD-L1 that suppress T cell-mediated damage and 
develop radiation resistance for relapse over time.  Anti-PDL-
1 antibody can greatly reduce radiation resistance leading to 
complete tumor regression.  Furthermore, our study 
challenges the rationale for current radio/chemotherapy 
strategies and highlights the importance of immune 
activation in preventing tumor relapse.   
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Cells respond to radiation. The best known pathways involve 
DNA repair and anti-apoptotic activities. These have different 
effects on the cell, its environment and the resulting immune 
response. We will discuss a new mechanism of DNA repair 
control that makes cells less responsive to radiation and DNA 
damaging chemotherapies. In addition, local radiotherapy 
can boost antibody-based triggering of immune responses to 
tumors but also makes the cells and environment more 
susceptible for CTL based therapies. This has allowed us to 
perform genome-wide screens to identify new and unknown 
factors controlling DNA repair and susceptibility to DNA 
damaging regimes in cancer therapy. We will discuss how 
